Clinical Trial Update: SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating SBRT for oligoprogressive non-small cell lung cancer after first-line immune checkpoint inhibitors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: NSCLC Stage IV | Phase 2 | Status: UNKNOWN